| Literature DB >> 28404755 |
William J Gradishar1, Benjamin O Anderson2, Ron Balassanian3, Sarah L Blair4, Harold J Burstein5, Amy Cyr6, Anthony D Elias7, William B Farrar8, Andres Forero9, Sharon Hermes Giordano10, Matthew P Goetz11, Lori J Goldstein12, Steven J Isakoff13, Janice Lyons14, P Kelly Marcom15, Ingrid A Mayer16, Beryl McCormick17, Meena S Moran18, Ruth M O'Regan19, Sameer A Patel12, Lori J Pierce20, Elizabeth C Reed21, Kilian E Salerno22, Lee S Schwartzberg23, Amy Sitapati4, Karen Lisa Smith24, Mary Lou Smith25, Hatem Soliman26, George Somlo27, Melinda Telli28, John H Ward29, Dorothy A Shead30, Rashmi Kumar30.
Abstract
These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.Entities:
Mesh：
Year: 2017 PMID： 28404755 DOI： 10.6004/jnccn.2017.0044
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908